Literature DB >> 21186347

A mammalian functional-genetic approach to characterizing cancer therapeutics.

Hai Jiang1, Justin R Pritchard, Richard T Williams, Douglas A Lauffenburger, Michael T Hemann.   

Abstract

Identifying mechanisms of drug action remains a fundamental impediment to the development and effective use of chemotherapeutics. Here we describe an RNA interference (RNAi)-based strategy to characterize small-molecule function in mammalian cells. By examining the response of cells expressing short hairpin RNAs (shRNAs) to a diverse selection of chemotherapeutics, we could generate a functional shRNA signature that was able to accurately group drugs into established biochemical modes of action. This, in turn, provided a diversely sampled reference set for high-resolution prediction of mechanisms of action for poorly characterized small molecules. We could further reduce the predictive shRNA target set to as few as eight genes and, by using a newly derived probability-based nearest-neighbors approach, could extend the predictive power of this shRNA set to characterize additional drug categories. Thus, a focused shRNA phenotypic signature can provide a highly sensitive and tractable approach for characterizing new anticancer drugs.

Entities:  

Mesh:

Year:  2010        PMID: 21186347      PMCID: PMC3070540          DOI: 10.1038/nchembio.503

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  37 in total

1.  Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Authors:  Ainslie B Parsons; Andres Lopez; Inmar E Givoni; David E Williams; Christopher A Gray; Justin Porter; Gordon Chua; Richelle Sopko; Renee L Brost; Cheuk-Hei Ho; Jiyi Wang; Troy Ketela; Charles Brenner; Julie A Brill; G Esteban Fernandez; Todd C Lorenz; Gregory S Payne; Satoru Ishihara; Yoshikazu Ohya; Brenda Andrews; Timothy R Hughes; Brendan J Frey; Todd R Graham; Raymond J Andersen; Charles Boone
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

2.  The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

Authors:  Justin Lamb; Emily D Crawford; David Peck; Joshua W Modell; Irene C Blat; Matthew J Wrobel; Jim Lerner; Jean-Philippe Brunet; Aravind Subramanian; Kenneth N Ross; Michael Reich; Haley Hieronymus; Guo Wei; Scott A Armstrong; Stephen J Haggarty; Paul A Clemons; Ru Wei; Steven A Carr; Eric S Lander; Todd R Golub
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

3.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Authors:  Ross A Dickins; Michael T Hemann; Jack T Zilfou; David R Simpson; Ingrid Ibarra; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2005-10-02       Impact factor: 38.330

5.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Authors:  Haley Hieronymus; Justin Lamb; Kenneth N Ross; Xiao P Peng; Cristina Clement; Anna Rodina; Maria Nieto; Jinyan Du; Kimberly Stegmaier; Srilakshmi M Raj; Katherine N Maloney; Jon Clardy; William C Hahn; Gabriela Chiosis; Todd R Golub
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

6.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.

Authors:  David E MacCallum; Jean Melville; Sheelagh Frame; Kathryn Watt; Sian Anderson; Athos Gianella-Borradori; David P Lane; Simon R Green
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 7.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

8.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Authors:  Richard T Williams; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-17       Impact factor: 11.205

9.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

10.  Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.

Authors:  P F Swann; T R Waters; D C Moulton; Y Z Xu; Q Zheng; M Edwards; R Mace
Journal:  Science       Date:  1996-08-23       Impact factor: 47.728

View more
  49 in total

1.  Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.

Authors:  Yun-Chi Tang; Hui Yuwen; Kaiying Wang; Peter M Bruno; Kevin Bullock; Amy Deik; Stefano Santaguida; Marianna Trakala; Sarah J Pfau; Na Zhong; Tao Huang; Lan Wang; Clary B Clish; Michael T Hemann; Angelika Amon
Journal:  Cancer Res       Date:  2017-08-03       Impact factor: 12.701

2.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Authors:  Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

Review 3.  Functional genomics to uncover drug mechanism of action.

Authors:  Sebastian M B Nijman
Journal:  Nat Chem Biol       Date:  2015-11-17       Impact factor: 15.040

Review 4.  Single-cell and multivariate approaches in genetic perturbation screens.

Authors:  Prisca Liberali; Berend Snijder; Lucas Pelkmans
Journal:  Nat Rev Genet       Date:  2014-12-02       Impact factor: 53.242

5.  Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Peter M Bruno; Wei Lin; Weixue Wang; Michael T Hemann; Stephen J Lippard
Journal:  Inorganica Chim Acta       Date:  2016-03-25       Impact factor: 2.545

Review 6.  Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

Authors:  Simon Vyse; Annie Howitt; Paul H Huang
Journal:  J Mol Biol       Date:  2017-05-03       Impact factor: 5.469

Review 7.  Understanding resistance to combination chemotherapy.

Authors:  Justin R Pritchard; Douglas A Lauffenburger; Michael T Hemann
Journal:  Drug Resist Updat       Date:  2012-11-17       Impact factor: 18.500

8.  Defining principles of combination drug mechanisms of action.

Authors:  Justin R Pritchard; Peter M Bruno; Luke A Gilbert; Kelsey L Capron; Douglas A Lauffenburger; Michael T Hemann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-18       Impact factor: 11.205

9.  Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.

Authors:  Kogularamanan Suntharalingam; Timothy C Johnstone; Peter M Bruno; Wei Lin; Michael T Hemann; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2013-09-16       Impact factor: 15.419

10.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.